[Systemic treatment of bone sarcoma, soft tissue sarcoma, GIST].

Area of Science:

• Medical Oncology
• Cancer Research
• Pharmacology

Background:

• Systemic treatments are integral to managing bone sarcomas (osteosarcomas, Ewing sarcomas) and soft tissue sarcomas.
• Established chemotherapies include doxorubicin, methotrexate, cisplatin, ifosfamide, and etoposide.
• The role of maintenance therapy with anti-angiogenic tyrosine kinase inhibitors is under investigation.

Purpose of the Study:

• To review current systemic treatment strategies for bone sarcoma, soft tissue sarcoma, and gastrointestinal stromal tumors (GIST).
• To highlight effective chemotherapeutic agents and targeted therapies.
• To address ongoing questions regarding adjuvant therapy optimization and treatment duration.

Main Methods:

• Review of established and emerging systemic treatment protocols.
• Analysis of drug efficacy based on sarcoma subtype and clinical setting (neo-adjuvant, adjuvant, metastatic).
• Consideration of ongoing clinical trials for maintenance therapy and extended adjuvant treatment.

Main Results:

• Anthracyclines remain a cornerstone for soft tissue sarcomas.
• Specific chemotherapy regimens are effective for osteosarcomas and Ewing sarcomas.
• For high-risk GIST, imatinib is standard adjuvant therapy, with ongoing studies on extending treatment to 6 years.
• Metastatic GIST is managed with sequential tyrosine kinase inhibitors (imatinib, sunitinib, regorafenib, riprenib).

Conclusions:

• Systemic chemotherapy and targeted therapies are vital in sarcoma treatment.
• Further research is needed to refine adjuvant therapy selection and duration.
• Personalized treatment approaches based on histological subtype and risk stratification are essential for optimizing outcomes.